The Synthesis of Chalcones as Anticancer Prodrugs and their Bioactivation in CYP1 Expressing Breast Cancer Cells
作者:Ketan C. Ruparelia、Keti Zeka、Taeeba Ijaz、Dyan N. Ankrett、Nicola E. Wilsher、Paul C. Butler、Hoon L. Tan、Sabahat Lodhi、Avninder S. Bhambra、Gerard A. Potter、Randolph R.J. Arroo、Kenneth J.M. Beresford
DOI:10.2174/1573406414666180112120134
日期:2018.5.11
Background: Although the expression levels of many P450s differ between tumour and
corresponding normal tissue, CYP1B1 is one of the few CYP subfamilies which is significantly
and consistently overexpressed in tumours. CYP1B1 has been shown to be active within tumours
and is capable of metabolising a structurally diverse range of anticancer drugs. Because of this,
and its role in the activation of procarcinogens, CYP1B1 is seen as an important target for anticancer
drug development.
Objective: To synthesise a series of chalcone derivatives based on the chemopreventative agent
DMU-135 and investigate their antiproliferative activities in human breast cancer cell lines which
express CYP1B1 and CYP1A1.
Method: A series of chalcones were synthesised in yields of 43-94% using the Claisen-Schmidt
condensation reaction. These were screened using a MTT assay against a panel of breast cancer
cell lines which have been characterised for CYP1 expression.
Result: A number of derivatives showed promising antiproliferative activities in human breast
cancer cell lines which express CYP1B1 and CYP1A1, while showing significantly lower toxicity
towards a non-tumour breast cell line with no CYP expression. Experiments using the CYP1 inhibitors
acacetin and α-naphthoflavone provided supporting evidence for the involvement of CYP1
enzymes in the bioactivation of these compounds.
Conclusion: Chalcones show promise as anticancer agents with evidence suggesting that CYP1
activation of these compounds may be involved.
背景:尽管许多 P450 在肿瘤和相应正常组织中的表达水平不同,CYP1B1 是少数在肿瘤中显著且一致过表达的 CYP 亚家族之一。研究表明,CYP1B1在肿瘤中具有活性,并且能够代谢结构多样的抗癌药物。因此,以及其在激活前致癌物中的作用,CYP1B1 被视为抗癌药物开发的重要靶点。
目标:基于化学预防剂 DMU-135 合成一系列查尔酮衍生物,并研究它们在表达 CYP1B1 和 CYP1A1 的人乳腺癌细胞系中的抗增殖活性。
方法:通过克来森-施密特缩合反应合成了产率为 43-94%的一系列查尔酮。这些化合物通过 MTT assay 对一组已知 CYP1 表达的乳腺癌细胞系进行了筛选。
结果:许多衍生物在表达 CYP1B1 和 CYP1A1 的人乳腺癌细胞系中显示出有前景的抗增殖活性,同时对没有 CYP 表达的非肿瘤乳腺癌细胞系显示出显著较低的毒性。使用 CYP1抑制剂 acacetin 和 α-naphthoflavone 的实验为这些化合物在生物激活过程中涉及 CYP1 酶提供了支持性证据。
结论:查尔酮作为抗癌药物显示出潜力,有证据表明这些化合物的 CYP1 激活可能参与其中。